Format

Send to

Choose Destination
Orphanet J Rare Dis. 2018 Dec 4;13(1):218. doi: 10.1186/s13023-018-0960-x.

The French National Registry of patients with Facioscapulohumeral muscular dystrophy.

Author information

1
Aix Marseille Univ, INSERM, MMG, Bioinformatics & Genetics, Marseille, France.
2
Université Côte d'Azur, Service Système Nerveux Périphérique, Muscle et SLA, Centre Hospitalier Universitaire de Nice, Nice, France.
3
APHM, Hôpital Timone Enfants, Laboratoire de Génétique Moléculaire, Marseille, France.
4
Institute for Research on Cancer and Aging of Nice (IRCAN), INSERM U1081, CNRS UMR 7284, Université Côte d'Azur (UCA), Faculté de Médecine, Nice, France.
5
Aix Marseille Univ, INSERM, MMG, Bioinformatics & Genetics, Marseille, France. christophe.beroud@inserm.fr.
6
APHM, Hôpital Timone Enfants, Laboratoire de Génétique Moléculaire, Marseille, France. christophe.beroud@inserm.fr.

Abstract

BACKGROUND:

Facioscapulohumeral muscular dystrophy is a rare inherited neuromuscular disease with an estimated prevalence of 1/20,000 and France therefore harbors about 3000 FSHD patients. With research progress and the development of targeted therapies, patients' identification through registries can facilitate and improve recruitment in clinical trials and studies.

RESULTS:

The French National Registry of FSHD patients was designed as a mixed model registry involving both patients and physicians, through self-report and clinical evaluation questionnaires respectively, to collect molecular and clinical data. Because of the limited number of patients, data quality is a major goal of the registry and various automatic data control features have been implemented in the bioinformatics system. In parallel, data are manually validated by molecular and clinical curators. Since its creation in 2013, data from 638 FSHD patients have been collected, representing about 21% of the French FSHD population. The mixed model strategy allowed to collect 59.1% of data from both patients and clinicians; 26 and 14.9% from respectively patients and clinicians only. With the identification of the FSHD1 and FSHD2 forms, specific questionnaires have been designed. Though FSHD2 patients are progressively included, FSHD1 patients still account for the majority (94.9%). The registry is compatible with the FAIR principles as data are Findable, Accessible and Interoperable. We thus used molecular standards and standardized clinical terms used by the FILNEMUS French network of reference centers for the diagnosis and follow-up of patients suffering from a rare neuromuscular disease. The implemented clinical terms mostly map to dictionaries and terminology systems such as SNOMED-CT (75% of terms), CTV3 (61.7%) and NCIt (53.3%). Because of the sensitive nature of data, they are not directly reusable and can only be accessed as aggregated data after evaluation and approval by the registry oversight committee.

CONCLUSIONS:

The French National Registry of FSHD patients belongs to a national effort to develop databases, which should now interact with other initiatives to build a European and/or an international FSHD virtual registry for the benefits of patients. It is accessible at www.fshd.fr and various useful information, links, and documents, including a video, are available for patients and professionals.

KEYWORDS:

Database; FSHD; FSHD1; FSHD2; Facioscapulohumeral muscular dystrophy; Myopathy; Patient registry

Supplemental Content

Full text links

Icon for BioMed Central Icon for PubMed Central
Loading ...
Support Center